Sat, Sep 20, 2014, 12:41 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Optimer Pharmaceuticals, Inc. (OPTR) Message Board

  • loriskhireward loriskhireward Jan 11, 2012 1:38 PM Flag

    Clinical outcomes stats don't lie...

    lol. Pro and jla hoped that they could ride out the long-term benefits of fida? haven't they seen the long-term benefits Dificid has over vanco? just curious...it's in the studies. Happy New Year, guys.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • so tired of hearing your blabbering, without substantiation. Keep your short position until you can't take the ramp-up anymore; then, my guess we'll no longer see you here lurking...can't wait.

    • you should be careful who you call ignorant, pot calling the kettle black....after all you are a Long in OPTR...LOL!

      Any way, the current significantly lowered revenue estimates prove my point and time will continue to prove me right....see you in single digits soon....

    • over time, you'll be proven wrong imo by the superb outcomes when patients are treated with Dificid. Docs, as well, will be proven wrong as more patients are readmitted because initial treatment left the door open for recurrence at TWICE the risk. The burden on the healthcare system is already documented, so we'll see how it's to be relieved...it will not be through "reasoning away" the use of the best drug due strictly to cost, imo. Let's see how CMS reacts to further first-line treatment using vanco, costs of continued recurrences at TWICE the rate as would be the case with Dificid...or whether they instruct providers to identify best outcomes and target them appropriately. Good luck on your side of the fence.

    • however, had FIDO showed superiority in initial outcomes, then FIDO could have a chance.....Nah, forget it, OPTR and FIDO stinks all around due to horrible IP, zero pipeline, extreme expenses, etc...

    • the reality is, that's how US healthcare works....to claim otherwise, you are being the idiot! Cure rates after 10-12 day treatment are EQUIVALENT! hey if Vanc or generic Vanc fix the problem after initial treatment, you'll be hard press to argue for the higher cost treatment. Every thing else is yada, yada, yada....

    • Is that what you do when you or your family is ill-- say give me and mine what's quickest and cheapest?
      Must make the the fam sleep better to know you'e watching out for them-------idiot.

    • recurrence rates dropped from ~24% to ~12% big whoopdee dooo! Initial cures were identical after treatment (~12 days). Oh, and long term outcomes between FIDO and VANC were identical for the highly virulent NAP1 strain....how do Longs explain that??? LONGS CAN'T!

      Any FIDO biggest issues are IP (long term exclusivity which will be highly challenge after 5 years), ZERO pipeline, and expenses out the wazooo! And and no buyout, sorry pumpers!

 
OPTR
12.780.00(0.00%)Oct 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Genworth Financial, Inc.
NYSEFri, Sep 19, 2014 4:03 PM EDT
AutoZone, Inc.
NYSEFri, Sep 19, 2014 4:02 PM EDT